Go Pro
NASDAQ:BIAF

bioAffinity Technologies Q4 2025 Earnings Report

bioAffinity Technologies logo
$7.65 -0.29 (-3.65%)
As of 12:11 PM Eastern
This is a fair market value price provided by Massive. Learn more.

bioAffinity Technologies EPS Results

Actual EPS
-$16.65
Consensus EPS
-$40.50
Beat/Miss
Beat by +$23.85
One Year Ago EPS
N/A

bioAffinity Technologies Revenue Results

Actual Revenue
$1.59 million
Expected Revenue
$1.55 million
Beat/Miss
Beat by +$39.81 thousand
YoY Revenue Growth
N/A

bioAffinity Technologies Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

bioAffinity Technologies' Q3 2026 earnings is estimated for Wednesday, November 18, 2026, based on past reporting schedules

bioAffinity Technologies Earnings Headlines

Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he says has never existed before. In a similar setup in the past, select investors saw $1,000 turn into over $1 million within a few years. Del Real just released a full video breakdown of what is driving this move and how to prepare.tc pixel
Four High-Impact Small Caps Enter the Spotlight
bioAffinity secures Hong Kong patent for CyPath Lung
See More bioAffinity Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like bioAffinity Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on bioAffinity Technologies and other key companies, straight to your email.

About bioAffinity Technologies

bioAffinity Technologies (NASDAQ:BIAF) is a biotechnology company focused on developing diagnostics and therapeutics for cancer and other serious diseases. The company’s technology uses porphyrin compounds that can selectively interact with cancer cells, supporting applications in both disease detection and treatment.

Its lead diagnostic product, CyPath Lung, is a noninvasive urine-based test designed to aid in the early detection of lung cancer. The test is intended to identify cancer-related signals in urine and is being developed as an alternative or complement to existing screening and diagnostic methods.

bioAffinity is also developing porphyrin-based therapeutic programs, including inhaled treatments intended to target cancer cells in the lungs. Founded in 2007 and headquartered in Albuquerque, New Mexico, the company is led by Maria Zannes, who serves as president and chief executive officer. Its products and programs remain subject to applicable clinical, regulatory, and commercialization requirements.

View bioAffinity Technologies Profile